DENTSPLY SIRONA (XRAY) Q4 2022 earnings summary

Executive summary

• FY22 described as challenging, with weak external conditions and internal underperformance; transformation priorities include profitability, digitalization, aligners and implants, and a higher-accountability operating model.

• 2023 characterized as a transition year, with annual revenue and margin delivery identified as priorities for rebuilding stakeholder confidence.

Financial highlights

• FY22 net sales were $3.922B, down 7.3% reported and 0.5% organically YoY; FX reduced sales by 6.8%.

• Net loss was $950M vs. $411M net income in FY21; diluted loss per share was $4.41 vs. diluted EPS of $1.87.

• Operating loss was $937M vs. operating income of $608M in FY21, primarily reflecting a $1.187B goodwill impairment charge.

• Operating cash flow was $517M vs. $657M; gross profit was $2.127B and gross margin was 54.2%, down 130 bps YoY.

Outlook and guidance

• FY23 is expected to be a transition year; priorities include meeting annual revenue and margin objectives and improving organizational efficiency and portfolio focus.

• Announced restructuring targets $200M–$225M in net annual savings, with substantial completion expected within 18 months.

• FY23 restructuring charges are expected to reach $165M: $130M of restructuring costs and $35M of other non-recurring costs; workforce reduction estimated at 8%–10%.

• FY23 capital expenditures are estimated at $150M–$170M, including facility expansion and consolidation investments.